I would agree. The savings on generics have allowed us, just like the Swedes, to buffer the additional growth in the prices of specialty drugs, so we've had a relatively flat budget for pharmaceuticals. This has also allowed us to take up the more expensive products, for instance, the orphan products.
However, for the orphan drugs, we're going to have managed entry agreements. As I said, this is based on the budgetary impact. If there is a large budgetary impact, we will engage in financial talks with the company before reimbursing those—that's also for out-patient drugs. Especially for orphan drugs with a high cost per patient, we will be asking the companies to engage in additional data collection, and also in finding the appropriate use, the right way of targeting the right population for these drugs. We are adding these things to our reimbursements.
We've been very lucky up to now to be able to do that, to incorporate most effective products in our reimbursement system, but it is increasingly a problem. That is also why, within the international realm, we've started collaborating with Belgium, Luxembourg, and Austria, just like the Nordic collaboration forum, where we are talking about pharmaceutical policies and where we engage in joint negotiations.